Geniom now at Prognosys and UCSF

Two renowned institutes decided to upgrade their genome analysis facilities by Geniom Technology

Heidelberg, (PresseBox) - According to the announcement made by febit inc. today, the operational business of the company in the U.S. has been started successfully: Within the last months the first Geniom Instruments have been installed at the renowned US-institutes Prognosys Bioscience, Inc in San Diego (CA). and University of California in San Francisco (UCSF).

Prognosys is the first research site in the US that decided last spring to establish the Geniom microarray platform as genetic analysis tool in their laboratory. Dr. Stefan Matysiak, Vice President & General Manger of febit inc., stated, “Prognosys is a crucial reference site for febit inc. Cooperations and clients like Marc Chee, founder and CEO of Prognosys, are extremely valuable in respect of a market characterized by particular dynamics and a high rate of innovation. We believe that in the near future the Geniom Technology will play an important role within the market of microarray analysis based on its high quality and unique flexibility.”

With the UCSF a very renowned and well equipped institute decided for Geniom to enhance the pool of cutting edge technology at its Center for Advanced Technology (CAT). To get Geniom-supported research up and running as soon as possible, febit sent as a part of its customer service a team of specialists to train the UCSF laboratory team onsite, and optimizes the highly-advanced system to the scientists needs.

febit inc., affiliated company of febit biotech gmbh from Heidelberg (Germany) commenced its operations in August, 2006 in Medford, Massachusetts (USA). During the last several months, febit inc. has built a powerful and competent team for sales, service and customer consulting and established an application lab for potential customers to test the Geniom platform’s ability to produce their specific requirements.

Hummingbird Diagnostics GmbH

Developing innovative and creative technologies for genomic research is the corporate mission of the febit group, a German-American biotech company. Geniom is a technological and service platform successfully used in basic and applied research of renowned institutions and companies. Geniom exploits cutting-edge microarray technology for analysis and synthesis of genes and genomes providing superior time and cost efficiency combined with an unsurpassed spectrum of applications (Geno-, SNP- and Pathogentyping, Enzyme-on-Chip, miRNA-Profiling and many more). With the unique Geniom Technology febit now enters the high-potential market of synthetic biology with a novel method for production of synthetic genes. Using both, highly integrated automation and extensive customizability, febit meets essential needs of current biomedical research.

Diese Pressemitteilungen könnten Sie auch interessieren

Weitere Informationen zum Thema "Medizintechnik":

Gluon – KI-Entwicklung leicht gemacht

Die De­ep-Lear­ning-Schnitt­s­tel­le Gluon (Open Sour­ce) er­mög­licht es Ent­wick­lern, sch­nel­ler und ein­fa­cher Mo­del­le für das Ma­chi­ne oder De­ep Lear­ning zu er­s­tel­len, oh­ne dass sich die Trai­nings­leis­tung un­ge­bühr­lich ver­län­gert. Gluon kann mit je­der be­lie­bi­gen KI-En­gi­ne ar­bei­ten.


News abonnieren

Mit dem Aboservice der PresseBox, erhalten Sie tagesaktuell und zu einer gewünschten Zeit, relevante Presseinformationen aus Themengebieten, die für Sie interessant sind. Für die Zusendung der gewünschten Pressemeldungen, geben Sie bitte Ihre E-Mail-Adresse ein.

Es ist ein Fehler aufgetreten!

Vielen Dank! Sie erhalten in Kürze eine Bestätigungsemail.

Ich möchte die kostenlose Pressemail abonnieren und habe die Bedingungen hierzu gelesen und akzeptiert.